| Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy A Ribas, R Dummer, I Puzanov, A VanderWalde, RHI Andtbacka, ... Cell 170 (6), 1109-1119. e10, 2017 | 1249 | 2017 |
| Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology JA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ... Journal of the National Comprehensive Cancer Network 17 (3), 255-289, 2019 | 490 | 2019 |
| Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology DG Coit, JA Thompson, MR Albertini, C Barker, WE Carson, C Contreras, ... Journal of the National Comprehensive Cancer Network 17 (4), 367-402, 2019 | 377 | 2019 |
| NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020: featured updates to the NCCN guidelines JA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ... Journal of the National Comprehensive Cancer Network 18 (3), 230-241, 2020 | 354 | 2020 |
| Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037) TC Mitchell, O Hamid, DC Smith, TM Bauer, JS Wasser, AJ Olszanski, ... Journal of Clinical Oncology 36 (32), 3223, 2018 | 305 | 2018 |
| Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology DG Coit, JA Thompson, A Algazi, R Andtbacka, CK Bichakjian, ... Journal of the National Comprehensive Cancer Network 14 (4), 450-473, 2016 | 250 | 2016 |
| Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors BI Rini, JH Schiller, JP Fruehauf, EEW Cohen, JC Tarazi, B Rosbrook, ... Clinical Cancer Research 17 (11), 3841-3849, 2011 | 216 | 2011 |
| Efficacy and safety of axitinib in patients with advanced non–small-cell lung cancer: results from a phase II study JH Schiller, T Larson, SHI Ou, S Limentani, A Sandler, E Vokes, S Kim, ... Journal of Clinical Oncology 27 (23), 3836-3841, 2009 | 202 | 2009 |
| NCCN Guidelines® insights: melanoma: cutaneous, version 2.2021: featured updates to the NCCN guidelines SM Swetter, JA Thompson, MR Albertini, CA Barker, J Baumgartner, ... Journal of the National Comprehensive Cancer Network 19 (4), 364-376, 2021 | 198 | 2021 |
| First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors KP Papadopoulos, L Gluck, LP Martin, AJ Olszanski, AW Tolcher, ... Clinical Cancer Research 23 (19), 5703-5710, 2017 | 192 | 2017 |
| Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors JR Infante, EC Dees, AJ Olszanski, SV Dhuria, S Sen, S Cameron, ... Journal of clinical oncology 32 (28), 3103-3110, 2014 | 192 | 2014 |
| Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology JA Thompson, BJ Schneider, J Brahmer, A Achufusi, P Armand, ... Journal of the National Comprehensive Cancer Network 20 (4), 387-405, 2022 | 176 | 2022 |
| Melanoma, version 2.2013: featured updates to the NCCN guidelines DG Coit, R Andtbacka, CJ Anker, CK Bichakjian, WE Carson, A Daud, ... Journal of the National Comprehensive Cancer Network 11 (4), 395-407, 2013 | 172 | 2013 |
| Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non–small … CJ Langer, S Novello, K Park, M Krzakowski, DD Karp, T Mok, RJ Benner, ... Journal of clinical oncology 32 (19), 2059, 2014 | 161 | 2014 |
| Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy A Ribas, R Dummer, I Puzanov, A VanderWalde, RHI Andtbacka, ... Cell 174 (4), 1031-1032, 2018 | 142 | 2018 |
| Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in … NL Lewis, LD Lewis, JP Eder, NJ Reddy, F Guo, KJ Pierce, AJ Olszanski, ... Journal of clinical oncology 27 (31), 5262, 2009 | 126 | 2009 |
| Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. GV Long, R Dummer, A Ribas, I Puzanov, A VanderWalde, ... Journal of Clinical Oncology 34 (15_suppl), 9568-9568, 2016 | 125 | 2016 |
| Current and future roles of targeted therapy and immunotherapy in advanced melanoma AJ Olszanski Journal of Managed Care Pharmacy 20 (4), 346-356, 2014 | 122 | 2014 |
| Association of diastolic blood pressure (dBP)≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736) BI Rini, JH Schiller, JP Fruehauf, EE Cohen, JC Tarazi, B Rosbrook, ... Journal of Clinical Oncology 26 (15_suppl), 3543-3543, 2008 | 109 | 2008 |
| NCCN guidelines insights: melanoma, version 3.2016 DG Coit, JA Thompson, A Algazi, R Andtbacka, CK Bichakjian, ... Journal of the National Comprehensive Cancer Network 14 (8), 945-958, 2016 | 105 | 2016 |
